A Phase 0 Single Microdose Study to evaluate the Pharmacokinetics of INS018_055 in Healthy Participants

Insilico Medicine Hong Kong Limited0 个研究点目标入组 8 人开始时间: 2021年11月11日最近更新: 2022年4月4日

试验速览

暂无简介。

•1. Healthy female or male aged 18 to 55 years (both inclusive) at screening.
•2. BMI of 17.50 to 30.50 kg/m2; and a total body weight more than 50 kg at screening and Day 1.
•3. Sufficient venous access for the purposes of the study.
•Participants must be a non-smoker and must not have used any tobacco products within two months prior to screening.
•4. Females must be non-pregnant and non-lactating.
•5. Willing and able to attend the trial visits and complete study assessments.
•6. Signed HREC approved Informed Consent Form.

•1. Positive toxicology screening panel
•2. Major surgery or significant trauma within 28 days (4 weeks) prior to screening
•3. BP more than 150 mm of Hg (systolic) or more than 95 mm of Hg (diastolic)
•4. Abnormalities in the clinical laboratory tests at screening
•5. A white Blood Cell count less than 4.5 x 109/L, including history of benign ethnic neutropenia
•6. Absolute neutrophil count of less than 2 X 109/L
•7. hematocrit below 0.4 for males and 0.35 for females.
•8. Use of any IP or investigational medical device within 30 days prior to Screening
•9.Use of prescription or non-prescription drugs and dietary supplements within 7 days or
•5 half-lives (whichever is longer)
•10. significant blood loss within 56 days prior to dosing.
•11. History of sensitivity to heparin or heparin-induced thrombocytopenia
•12. Have a history of any lymphoproliferative disorder
•13. Have a clinically significant infection currently or within 6 months of first dose of study
•14. Test positive at Screening for HIV, hepatitis B or C viruses
•15. History of malignancy or severe allergic reactions
•16. Pregnant or lactating women

发起方